

ABSTRACT SUBMISSION GUIDELINES FOR MODERATED POSTER AND PODIUM SESSIONS

On-line Abstract Submission Process Begins: August 3, 2009

Abstract Deadline Date: November 16, 2009 @ 11:59 PM EST

Submitted abstracts are graded individually by peer reviewers based on scientific merit and originality. Accepted abstracts are assigned to be presented in a podium session or a moderated poster session. The AUA Program Committee will determine the format of presentation. Abstracts must be written in English and, if accepted, presented in English. **Multiple abstracts by the same authors based on the same study population or data will be rejected outright.**

Preparation of Abstracts

- 1. Size:** The size of the abstract is limited to 2,280 characters not including spaces. This includes title, body of abstract, tables and graphics. Tables are calculated at 250 characters. Graphics are calculated at 225 characters per graphic.
- 2. Title:** The title should clearly define the topic and contain no abbreviations.
- 3. Authors:** List the primary author's full name, followed by the other authors' names. Spell out completely the names of all authors using full first name, middle initial and last name. (Maintain consistency in authors' names on multiple abstracts to avoid duplication in the Author Index.)
- 4. Presenting Author: If the author(s) of the abstract is an employee(s) of or has a financial relationship with the commercial interest which controls the content of the presentation then he/she cannot be the presenting author.** In all printed publications the presenting author will be denoted with an asterisk (*). **Please note:** As of January 18, 2010, any changes to the Presenting Author will not be published in the Program Abstract Book.
- 5. Body of Abstract:** The abstract should be informative and detailed.
 - The body must contain 4 separate paragraphs: a) Introduction and Objective, b) Methods, c) Results and d) Conclusions.
 - It is NOT acceptable to state that "The results will be discussed." Inclusion of specific data is helpful to the reviewers.
 - Indicate the major new findings of the study.
 - Standard abbreviations may be used as follows: on first use spell out the full term and follow with the abbreviation in parentheses.
 - Graphs and/or tables may be used; characters in graphs and tables are counted towards the overall character limit of the abstract.
 - Proprietary names of drugs are not allowed; generic names must be used.

6. Source of Funding: Grant support must be indicated on the "Source of Funding" page. If there is no support, "none" must be listed. This is a required field in the submission process. **Abstracts deemed to be purely for marketing purposes will not be accepted.**

7. Conflict of Interest and Disclosure Statement: All authors must disclose conflicts of interest. The electronic submission process will not allow abstracts to be submitted without this information being completed for each author listed on the abstract.

8. Topic List: Authors must select an abstract topic (only one) from the provided list.

9. Keywords: Authors must select up to 3 keyword entries from the provided Keyword Index that best describes the subject of the abstract.

10. Pediatric Submissions: Authors submitting pediatric abstracts must select 1 of the following venues: World Congress of Pediatric Urology, AUA Annual Meeting, No Preference.

LATE-BREAKING ABSTRACT SUBMISSION GUIDELINES

The Late-Breaking Abstract Submission site opens November 23, 2009 and closes January 15, 2010 @ 11:59 PM EST

AUA's late-breaking abstract policy allows the submission of late-breaking abstracts only for trials for which no preliminary data are available at the time of the abstract submission deadline (November 16, 2009). **The policy is not a mechanism to allow for updated data to be submitted late when preliminary data are available by the abstract submission deadline or to provide an opportunity for previously rejected abstracts to be revised and resubmitted for consideration.**

Preparation of Abstracts: Follow steps 1 to 9.

These abstracts are intended to allow for the timely presentation of late-breaking news of interest to annual meeting attendees. Priority will be given (in the following order) to:

- Results of phase III clinical trials
- Results of phase II clinical trials
- Extraordinary findings from a basic science investigation
- Interim analyses of phase III trials that describe important second end points
- Prospective multi-institution clinical trials

The authors must fully describe all funding sources for their investigation. **Newsworthy trials for which the author(s) is compelled not to publish the results (even in abstract form) may be submitted without written final conclusions as long as the author(s) signs a declaration stating that the final conclusions will be presented in full at the AUA annual meeting.**